www.fdanews.com/articles/195161-tecentriq-approved-for-metastatic-non-squamous-non-small-cell-lung-cancer
![Grey Approved Stamp](https://www.fdanews.com/ext/resources/test/Drug-Images4/Grey_Approved_Stamp.gif?t=1576541258&width=430)
Tecentriq Approved for Metastatic Non-Squamous Non-Small Cell Lung Cancer
December 16, 2019
The FDA approved Roche’s Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer.
The approval was based on the results of a phase 3 multicenter study in which Tecentriq plus chemotherapy demonstrated significant overall survival and progression-free survival.
Roche currently has nine phase 3 Tecentriq trials underway for lung cancer, and multiple ongoing and planned trials for genitourinary, skin, breast, gastrointestinal, gynecological, and head and neck cancers.